BERKELEY HEIGHTS, N.J., June 18, 2012 (GLOBE NEWSWIRE) -- Genta Incorporated (GNTA) announced that the Company's Chairman and Chief Executive Officer, Dr. Raymond P. Warrell, Jr., will provide a company overview and status update of recent research at the Business Forum during the BIO International Convention on Wednesday, June 20, 2012, at 8:30 AM EDT.

The conference will be held at The Boston Convention and Exhibition Center, Boston, MA. Further information about the 2012 BIO International Business Forum is available at: http://convention.bio.org/businessforum/.

About Genta

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer.  The Company is developing tesetaxel, a novel, orally absorbed taxane that is in the same class of drugs as paclitaxel and docetaxel.  As the leading oral taxane in clinical development, tesetaxel is being evaluated in randomized clinical trials that compare tesetaxel with standard chemotherapy in patients with gastric cancer and breast cancer, and as a single agent in prostate cancer. Genta is also exclusively marketing Ganite^® (gallium nitrate injection) in the U.S, which is indicated for treatment of symptomatic patients with cancer-related hypercalcemia that is resistant to hydration.  The Company has developed proprietary oral formulations of the active ingredient in Ganite^® that may be useful as potential treatment for diseases associated with accelerated bone loss.  For more information about Genta, please visit our website at: www.genta.com.

Safe Harbor

This press release may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Such forward-looking statements include those that express plan, anticipation, intent, contingency, goals, targets, or future developments and/or otherwise are not statements of historical fact. The words "potentially", "anticipates", "projects", "expects", "could", "calls for", and similar expressions also identify forward-looking statements. The Company does not undertake to update any forward-looking statements. Factors that could affect actual results include, without limitation, risks associated with:

• the Company's ability to obtain necessary regulatory approval for its product candidates from regulatory agencies, such as the U.S. Food and Drug Administration and the European Medicines Agency;
• the safety and efficacy of the Company's products or product candidates;
• the commencement and completion of any clinical trials;
• the Company's assessment of its clinical trials;
• the Company's ability to develop, manufacture, license, or sell its products or product candidates;
• the Company's ability to enter into and successfully execute any license and collaborative agreements;
• the adequacy of the Company's capital resources and cash flow projections, the Company's ability to obtain sufficient financing to maintain the Company's planned operations, or the risk of bankruptcy;
• the adequacy of the Company's patents and proprietary rights;
• the impact of litigation that has been brought against the Company; and
• the other risks described under Certain Risks and Uncertainties Related to the Company's Business, as contained in the Company's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q.

There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see the Company's most recent Annual Report on Form 10-K and its most recent quarterly report on Form 10-Q.